AstraZeneca Pharma P/E Ratio
Current P/E Ratio
98.37
High Valuation
Very High - High growth expectations or significantly overvalued
AstraZeneca Pharma (ASTRAZEN) P/E ratio is 98.37 (High), EPS (TTM) ₹75.01, current price ₹6751.50 on NSE — Very High - High growth expectations or significantly overvalued.
Current Valuation Metrics
P/E Ratio
98.37
Current Price
₹6751.50
EPS (TTM)
₹75.01
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
56.59
Sector Median
31.66
Sector Rank
#11 of 199
Sector Percentile
5.5%
ASTRAZEN P/E Ratio — Valuation Signal & Historical Context
AstraZeneca Pharma P/E 98.37 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see AstraZeneca Pharma share price chart.
- Stock appears overvalued with PE of 98.37, suggesting caution for new investments
- Trading at premium to sector average PE of 56.59
ASTRAZEN vs Healthcare Peers — P/E Ratio Comparison
AstraZeneca Pharma P/E 98.37 vs Healthcare average 56.59, median 31.66 — range 1.99–747.21.
Sector Average
56.59
Sector Median
31.66
Lowest P/E
1.99
Highest P/E
747.21
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 1.99 | ₹66 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Colinz Laboratories | COLINZ | 3.27 | ₹9 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.03 | ₹6,361 | Low |
| Dipna Pharmachem | DPL | 4.65 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.95 | ₹67 | Low |
| Shelter Pharma | SHELTER | 5.71 | ₹56 | Low |
| GKB Ophthalmics | GKB | 5.9 | ₹33 | Low |
| Kabra Drugs | KABRADG | 6.29 | ₹49 | Low |